NTLA Intellia Therapeutics
- 16.730
- +0.730+4.56%
- 16.730
- 0.0000.00%
Intellia Therapeutics News
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $45 to $60
Intellia Therapeutics Is Maintained at Overweight by Barclays
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $40 to $88
Express News | Intellia Therapeutics, Inc : Barclays Cuts Target Price to $55 From $76
Intellia Therapeutics | 10-Q: Q3 2024 Earnings Report
Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript Summary
Intellia Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
Intellia Ended The Third Quarter Of 2024 With Approximately $944.7M In Cash, Cash Equivalents And Marketable Securities, The Cash Position Is Expected To Fund Operations Into Late 2026
Intellia Therapeutics 3Q Rev $9.11M >NTLA
Express News | Intellia Therapeutics Q3 Basic EPS USD -1.34
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Express News | Intellia Therapeutics Q3 Net Income USD -135.712 Million
A Glimpse of Intellia Therapeutics's Earnings Potential
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
Express News | Intellia Therapeutics Inc : Leerink Partners Cuts Target Price to $51 From $60
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Beam Falls After Fatality in Gene Editing Trial
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $41
Intellia Therapeutics: Positive Outlook and Buy Rating Amid Promising Data for ATTR-CM Treatment
Analysis
Price Target
No Data
No Data
